HKD 64.85
+2.37%Oct 29, 2026, 09:36 UTC
RemeGen reported first-nine-month 2026 revenue of 6.764 billion yuan, up 293.28% year over year, net profit attributable to shareholders of 5.273 billion yuan, and adjusted net profit of 4.412 billion yuan.
Source:Oct 29, 2026, 09:36 UTC
RemeGen reported third-quarter 2026 revenue of 910 million yuan, up 46.41% year over year, net profit attributable to shareholders of 611 million yuan, and adjusted net profit of 73.6917 million yuan.
Source:Oct 28, 2026, 08:59 UTC
RemeGen said its controlling shareholder and chairman, Wang Weidong, proposed that the company repurchase A shares for RMB 30 million to RMB 60 million, at no more than 150% of the average trading price in the 30 trading days before board approval.
Source:Oct 22, 2026, 20:05 UTC
RemeGen reported that telitacicept preserved kidney function in the Phase 3 TELIGAN trial, with an annualized eGFR slope of -0.6 versus -5.7 mL/min/1.73 m² per year for placebo, a treatment difference of 5.1 mL/min/1.73 m² per year.
Source:Sep 29, 2026, 12:05 UTC
Vor Bio announced a new post hoc analysis from a Phase 3 trial conducted in China by RemeGen evaluating telitacicept in adults with generalized myasthenia gravis, showing deep and durable minimal symptom expression through 48 weeks.
Source:Sep 21, 2026, 02:12 UTC
Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.
Source:Sep 11, 2026, 10:05 UTC
RemeGen Co., Ltd. repurchased 19,000 A-shares on the Shanghai Stock Exchange via centralized bidding on September 11, 2026, at RMB 113.2-113.7 per share for a total of RMB 2.1552 million, to be used for an employee equity incentive plan.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 24, 2026, 09:34 UTC
RemeGen Co., Ltd. announced its 2026 interim results, reporting a net profit of 4.662 billion yuan, turning from a loss in the prior year.
Aug 21, 2026, 11:48 UTC
AbbVie presented clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer, including Phase 1b results for ABBV-1480 and a Phase 1b/2 study for telisotuzumab adizutecan.
Source:Aug 18, 2026, 19:54 UTC
RemeGen forecast first-half 2026 revenue of 5.85 billion yuan.
Aug 5, 2026, 13:29 UTC
RemeGen issued a profit alert, expecting a net profit of about 4.7 billion RMB for the six months ended June, turning from a loss of 450 million RMB in the same period last year; revenue was about 5.85 billion RMB, up 433% year-on-year.
Source:Jul 20, 2026, 02:00 UTC
Multiple A-share listed companies including Victory Giant Technology, RemeGen, and Huaan Securities issued share buyback announcements.
Jul 19, 2026, 08:43 UTC
Rongchang Biologics announced a share buyback plan of 25-50 million yuan at a price not exceeding 149 yuan per share.
Jun 8, 2026, 12:31 UTC
China's NMPA approved telitacicept for the treatment of Sjögren's disease in adult patients, based on Phase 3 results from RemeGen.